| Literature DB >> 32558361 |
Shigenori Kanno1, Mayumi Shinohara1, Kasumi Kanno1, Yukihiro Gomi1,2, Makoto Uchiyama1,3, Yoshiyuki Nishio1,4, Toru Baba1,5, Yoshiyuki Hosokai1,6, Atsushi Takeda5, Hiroshi Fukuda7,8, Etsuro Mori1,9, Kyoko Suzuki1.
Abstract
INTRODUCTION: The neural substrates associated with the development of micrographia remain unknown. We aimed to elucidate the neural substrates underlying micrographia in Parkinson's disease (PD) patients.Entities:
Keywords: Parkinson's disease; anterior cingulate cortex; micrographia; positron emission tomography; supplementary motor area; visual cortex
Mesh:
Year: 2020 PMID: 32558361 PMCID: PMC7428504 DOI: 10.1002/brb3.1669
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Demographic characteristics of the subjects
| Variables | PD | HCs |
|
|---|---|---|---|
| Number | 40 | 20 | |
| Age (years) | 68.0 ± 6.6 | 69.4 ± 4.8 | .403 |
| Sex (women/men) | 26/14 | 17/3 | .105 |
| Education attainment (years) | 12.0 ± 1.9 | 12.7 ± 2.3 | .258 |
| MMSE score | 27.8 ± 2.0 | 28.8 ± 1.9 | .059 |
| Hoehn‐Yahr stage | 2.81 ± 0.51 | ||
| UPDRS motor score | 19.0 ± 8.0 | ||
| Brady/hypokinesia score | 6.5 ± 3.5 | ||
| Disease duration (years) | 8.1 ± 4.6 | ||
| Levodopa equivalent dose (mg/day) | 516 ± 280 |
Data are given as mean ± SD except for sex. Brady/hypokinesia score = the sum of scores finger taps, hand movements, rapid alternating movements of hands, leg agility, and body brady/hypokinesia from UPDRS motor part. Levodopa equivalent dose = regular levodopa dose 1 + slow‐release levodopa × 0.75 + bromocriptine × 10 + apomorphine × 10 + ropinirole × 20 + pergolide × 100 + pramipexole × 100 + [regular levodopa dose + (slow‐release levodopa × 0.75)] × 0.2 if taking entacapone.
The two‐sample t test was used except for sex (the chi‐square test).
Abbreviations: HCs, healthy controls; MMSE, Mini‐Mental State Examination; PD, Parkinson's disease; UPDRS, Unified Parkinson's Disease Rating Scale.
FIGURE 1(a) A sample case showing progressive micrographia (PM) in the free writing task in patients with Parkinson's disease (PD). In this case, the B value (the slope of the regression line) was −1.454, and the Corrected B value (corrected for the mean locus length) was −3.441. The locus length of the first letter was 18.8 mm, and the mean locus length was 12.1 mm. (b) A sample case of PM in the copying task in patients with PD. In this case, the B value was −0.994, and the Corrected B value was −1.815. The locus length of the first letter was 18.5 mm, and the mean locus length was 13.9 mm. (c) The process of detecting PM. The scanned letters were skeletonized, and the locus length of each letter (the total number of pixels of skeletonized letter; 1 mm = 7.8788 pixels) was measured. To determine whether the written letters revealed PM, we conducted a linear regression analysis. The regression line was obtained by the least squares method (with the ordinal number of the letter as the dependent variable and the locus length of the letter as the independent variable), and the slope of the regression line (the B value) was calculated. The Corrected B value was also calculated because the absolute value of the B value increases in proportion to the mean locus length of the letters, which leads to overestimations of the decreases in the locus lengths in subjects with large letter sizes
The results of experimental writing test. (a) Parkinson's disease versus Healthy controls. (b) The subjects with versus without selective consistent or progressive micrographia
| (a) | ||||
|---|---|---|---|---|
| Tasks | Variables | PD ( | HCs ( |
|
| Free writing | Prevalence of CM | 1 (2.5%) | 0 (0%) | .476 |
| Prevalence of PM | 6 (15%) | 2 (10%) | .591 | |
| Prevalence of PMa | 4 (10%) | 2 (10%) | 1.000 | |
| First letter size | 23.5 ± 6.9 mm | 31.0 ± 13.2 mm | .025 | |
| Mean letters size | 23.2 ± 8.2 mm | 28.7 ± 9.5 mm | .025 | |
| Corrected | −0.24 ± 2.24 | −0.04 ± 1.55 | .733 | |
| Copying | Prevalence of CM | 1 (2.5%) | 0 (0%) | .476 |
| Prevalence of PM | 7 (17.5%) | 0 (0%) | .047 | |
| Prevalence of PMa | 3 (7.5%) | 2 (10%) | .741 | |
| First letter size | 21.7 ± 3.7 mm | 21.9 ± 4.8 mm | .817 | |
| Mean letters size | 22.8 ± 4.8 mm | 25.3 ± 3.9 mm | .048 | |
| Corrected | 0.56 ± 2.07 | 1.10 ± 1.11 | .276 | |
Data are given as mean ± SD in Table 2A and as median (quartile, range) in Table 2B. The brady/hypokinesia score = the sum of scores finger taps, hand movements, rapid alternating movements of hands, leg agility, and body brady/hypokinesia from UPDRS motor part. LED = regular levodopa dose 1 + slow‐release levodopa × 0.75 + bromocriptine × 10 + apomorphine × 10 + ropinirole × 20 + pergolide × 100 + pramipexole × 100 + [regular levodopa dose + (slow‐release levodopa × 0.75)] × 0.2 if taking entacapone.
The two‐sample t test with the Bonferroni correction (a post hoc analysis after a two‐way repeated‐measures ANOVA) was used except for prevalence (the chi‐square test) in Table 2A, and the Mann–Whitney U test was used in Table 2B.
Abbreviations: CM, consistent micrographia; HCs, healthy controls; LED, levodopa equivalent dose; ND, not detected; PD, Parkinson's disease; PM, progressive micrographia; PMa, progressive macrographia; UPDRS, Unified Parkinson's Disease Rating Scale.
FIGURE 2The results of two‐way repeated‐measures ANOVA. (a) For the size of the first letter, there was a significant interaction between Group (Parkinson's disease and healthy controls) and Task (free writing and copying). (b) For the mean letter size, there was no significant interaction between Group and Task and no significant main effect of Task, whereas there was a significant main effect of Group. (c) For the Corrected B value, there were no significant interactions between Group and Task and no significant main effect of Group, whereas there was a significant main effect of Task. *p < .05. **p < .005. ***p < .001. HCs, healthy controls, NS, not significant; PD, Parkinson's disease
FIGURE 3The results of voxel‐based comparisons of brain glucose metabolism between patients with Parkinson's disease (PD) and healthy controls (HCs). (a) PD patients with progressive micrographia (PM) versus HCs (black‐red‐yellow‐white) and PD patients without PM versus HCs (blue‐green) in the free writing task. (b) PD patients with progressive micrographia (PM) versus HCs (black‐red‐yellow‐white) and PD patients without PM versus HCs (blue‐green) in the copying task. The models were adjusted for the possible confounding effects of age and sex. The colored bars indicate the t values. HCs, healthy controls; PD, Parkinson's disease; PM, progressive micrographia
FIGURE 4The results of the voxel‐based comparisons of brain glucose metabolism between Parkinson's disease (PD) patients with and without progressive micrographia (PM) and voxel‐based linear regression analyses within PD patients. (a) The PD patients with versus without PM (black‐red) and the clusters in which glucose metabolism was positively correlated with the Corrected B values (black‐violet) in the free writing task. The blue vertical line in the sagittal plane penetrates the anterior commissure and is perpendicular to the anterior–posterior commissure line (sky blue horizontal line), which was used to divide the supplementary motor area (SMA) into the pre‐SMA (anterior part) and SMA‐proper (posterior part). (b) The PD patients with versus without PM (black‐red) and the clusters in which glucose metabolism was positively correlated with the Corrected B values (black‐violet) in the copying task. To confine our analysis to regions showing hypometabolism in the patients relative to the healthy controls, a resulting map of the comparison between the patients with CM and selective PM and the healthy controls, with a liberal statistical threshold (p < .05, uncorrected), for each task was used for masking. The colored bars indicate the t values. PD, Parkinson's disease; PM, progressive micrographia
The results of FDG‐PET study. (a) Brain regions in which regional cerebral glucose metabolism was decreased in PD patients with progressive micrographia compared to those without progressive micrographia. (b) Brain regions in which regional cerebral glucose metabolism was positively correlated with corrected B values in PD patients without progressive micrographia
| (a) | ||||||
|---|---|---|---|---|---|---|
| Task | Regions (BA) | MNI coordinates |
| Cluster size | ||
|
|
|
| ||||
| Free writing | Right middle cingulate cortex (32) | 10 | 20 | 32 | 3.88 | 67 |
| Copying | Right superior occipital gyrus (19) | 26 | −66 | 24 | 4.33 | 104 |
Abbreviations: BA, Brodmann area; MNI, Montreal Neurological Institute.